B. Braun News

B. Braun Group increases sales and earnings

Dialysis business especially dynamic.

  • Revenue up by 5 % to € 5,429.6 million (previous year: € 5,169.5 million)
  • Consolidated net income up by 0.3 % to € 316.3 million (previous year: € 315.5 million)
  • EBITDA  € 798.4 million (previous year: € 784.9 million, + 1.7 %)
  • Expenditures on research and development up by 4.7 % to € 228.8 million (previous year: € 218.6 million)
  • Equity capital up by 4.9 % to € 2,564.0 million (previous year: € 2,445.0 million)
  • Number of employees worldwide increased by 8.3 % percent to 54,017 (previous year: 49,889); in Germany, up by 7 % to 13,616 (previous year: 12.726)  
  • Investments in new factories, dialysis centers, and strategic holdings remain at a very high level of € 0.9 billion (previous year: € 1.0 billion)

Melsungen. In fiscal year 2014, B. Braun Melsungen AG increased sales by 5 percent to € 5,429.6 million (previous year: € 5,169.5 million). Consolidated net income rose slightly by 0.3 percent to € 316.3 million (previous year: 315.5 million euros). "The B. Braun Group is in a good and stable economic condition," said CEO Dr. Heinz-Walter Große at the annual press conference on March 27 in Melsungen, where he presented the financial figures along with CFO Dr. Annette Beller. The increasing price competition in the healthcare market and tougher regulations on the marketing of medical and pharmaceutical products worldwide presented the company with greater challenges, however.

Developing divisions
The B. Braun Avitum Division showed particularly dynamic development. It increased its revenue by 20.5 percent to € 737.9 million (previous year: 612.5 million euros). In the product business areas, dialyzers, filters, and dialysis machines were particularly successful. Germany, Russia, Colombia, and the Netherlands were the main countries driving growth in the provider sector.

Hospital Care, B. Braun's largest division, increased revenue by 2.2 percent to € 2,527.8 million (previous year: € 2,474.4 million). Products for hospital primary care in infusion therapy, e.g. intravenous catheters and infusion devices, were in especially strong demand.

The Aesculap Division generated revenues of € 1,497.7 million for the reporting year, (previous year: € 1,444.2 million) and is therefore 3.7 percent over the previous year. Growth came from the Closure Technologies and surgery sectors. The orthopedics sector fell slightly below the previous year due to a difficult market environment.

The OPM (Outpatient Market) Division achieved revenues of € 643.9 million (previous year: € 609.0 million), which represents a 5.7 percent increase over the previous year. The wounds and incontinence care areas grew at an above-average rate.